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The Historical Sertoli Cell
The Sertoli cell has always been depicted as a critical cell type within the testis even in the first paper by Enrico Sertoli. When describing the Sertoli cells, he used the term ''mother cells,'' suggesting a unique role for these cells in germ cell maturation and development [1] . In the 1950s, with the use of better microscopy, Enrico Sertoli's intuitive observations were confirmed [2] . Scientists determined that Sertoli cells stretch from the basement membrane to the lumen and are in intimate contact with germ cells as they mature and develop into viable sperm. Later, the Sertoli cell was recognized as a major orchestrator of the testis during sex differentiation and gonadal development since it expresses Sry [3] and initiates the cascade of gene expression that regulates both seminiferous cord formation and sex-specific vascular development [4] [5] [6] . Thus, there is no denying that the Sertoli cell has a critical function in testis development, spermatogenesis and male fertility.
Immunoprivileged Functions of Sertoli Cells
Interestingly, the Sertoli cell has other functions that, when exploited, may also allow for this cell to deliver therapeutic proteins within tissues to treat disease. The testis, along with the placenta, the anterior chamber of the eye, and the brain, are all immunoprivileged sites within the body [7, 8] . In the testis, the blood-testis barrier (BTB) has long been considered the main defense against invading immune cells that may attack immunogenic germ cells. The BTB is composed of Sertoli cell tight junctions, the body of the Sertoli cell, and peritubular cells [9] [10] [11] . The Sertoli cell by itself has immune privilege properties and is a major component of the defense against the immune system [12] (Fig. 1) . The Sertoli cell produces many factors, such as Fas Ligand (FasL) [13] , Transforming Growth Factor B1 (TGFB1) [14] , Clusterin [15] , decay activating factor (DAF), and CD59 [16, 17] , which are believed to be immunoprotective and anti-inflammatory and/ or able to reduce complement activation. Sertoli cells have been shown to inhibit the humoral and cell-mediated immune response [18] . Complement activation plays an integral role in the process of humoral immune-mediated rejection; thus, factors that inhibit complement activation will reduce rejection of allografts (transplantation of cells, tissue, or organs to a recipient from genetically nonidentical donor of same species) and xenografts (transplant of cells and so on from one species to another) [19] . Sertoli cells have been demonstrated to inhibit antibody/complement-mediated cell lysis (Fig. 1) ; however, how they do this is yet undetermined [20] . Sertoli cells are hypothesized to secrete complement inhibitors that presumably coat the surface of differentiating germ cells as they move through the Sertoli cell and become haploid and are present on spermatozoa to prevent attack and removal within the female reproductive tract by complement lysis [21, 22] . These complement inhibitors would protect against antibodies recognizing them as foreign and initiating activation of the enzymatic cascade leading to the formation of the membrane attack complex, which results in cellular lysis [19, 20] .
Use of Sertoli Cells for Cell Mediated Gene Therapy
Sertoli cells were first determined to increase survival of pancreatic islet cells in allografts transplanted into male and female diabetic rats in 1993 [23] . Two years later, transplantation of testicular cells or Sertoli cells expressing CD95 ligand (FasL) allowed for allograft survival, while testicular and Sertoli cells that had a mutant nonfunctional CD95 ligand resulted in allograft rejection [13] . Later, in 1996, the first xenograft with Sertoli cells would be transplanted into the rat brain, where they would survive and provide immunoprotection [24] . In 2004, Dufour et al. [25] demonstrated that Sertoli cells expressing GFP could survive as allografts and maintain expression of GFP for at least 60 days. Sertoli cells were also transduced with recombinant adenoviral vectors carrying human neurotrophin-3 (hNT-3) in order to treat spinal injuries, where they produced biologically relevant levels of hNT-3, but this expression was transient [26] . In a recent article, Sertoli cells from prepubertal mice and pigs were transduced with an adenoviral vector containing furin-modified human proinsulin cDNA, which restored normal blood glucose levels in diabetic immunocompromised mice after transplantation [27] . However, this restoration of normoglycemia was also transient due to the use of the adenoviral transduction. Since the Sertoli cells were prepubertal, they were still proliferating, and new cells did not contain the transgene. In addition, the use of immunocompromised mice did not test how these Sertoli cells would survive in a system where the immune system was functional.
Kaur et al. [28] exploited an immortalized Sertoli cell line (MSC-1) transduced with lentiviral particles carrying furinmodified human proinsulin cDNA and ZsGreen Fluorescent protein downstream of the elongation factor 1 alpha promoter (MSC-EhI-Zs). Their goal was to achieve stable expression of insulin and maintain normal glucose levels in diabetic mice. Allotransplants with the MSC-EhI-Zs Sertoli cell line had 88% graft survival at 20 days and 75% at 50 days posttransplantation. Transplanted cells continued to produce insulin mRNA throughout the study, but insulin protein was produced at levels 100-fold less than previously demonstrated in primary Sertoli cells from pigs and mice that were transduced with an adenoviral vector. On analysis of blood from these mice, there was no significant change in blood glucose levels in the transplant recipients. However, isolation and culture of the transplanted MSC-EhI-Zs cells demonstrated that these cells continued to express insulin protein throughout the study. Even though insulin expression was not of a sufficient level to maintain glucose homeostasis within the blood of these mice, these cells may be useful in other gene therapy situations where low levels of expression are adequate (e.g., hemophilia and spinal cord injury). Future studies are under way to generate a vector that will provide increased levels of insulin expression that could maintain normal blood glucose levels on a long-term basis, so stay tuned for the current author's next publication.
Although the results presented by Kaur et al. [28] did not demonstrate a perfect system, this study takes us one step closer to exploiting Sertoli cells as a vehicle for cell-based gene therapy. The use of immunoprivileged cells such as Sertoli cells, which are engineered to secrete a protein of interest in an attempt to restore homeostasis in chronic diseases, is a major step in achieving successful cell mediated gene therapy. While cells can be engineered to produce and secrete particular proteins, these cells often stimulate an immune response that will result in cell loss and/or reduced therapeutic actions. Most of the time when cells are transplanted into animal models, a series of injections are required to suppress the host's immune system. Immunosuppression creates its own problems, including a reduced ability to fight off other infections. Since Sertoli cells can be transplanted without host immunosuppression, this would overcome the obstacle of immune rejection. If Sertoli cells can be engineered to secrete the necessary proteins of interest at levels capable of restoring normal cell and metabolic function, then they would show extreme promise for allowing for successful gene therapy procedures.
The Sertoli Cell of the Future
There is a niche in biomedical research for immunoprivileged cells, such as the Sertoli cell, to have great impacts on cell-mediated gene therapy and treatment of chronic disease. When Enrico Sertoli [1] examined these cells and described their function in 1865, he probably would have never imagined their use for cell-mediated gene therapy. Furthermore, reproductive biologists may never have considered making transgenic mice that overexpress therapeutic proteins within Sertoli cells for treatment of hemophilia, type 1 diabetes, or spinal cord injuries. It is certain that understanding more about the Sertoli cell will have great impact on male reproduction; however, now there may be even a greater impact on the field of gene therapy. 
